The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 06, 2022

Filed:

Nov. 11, 2021
Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Jiuyi Lu, Topsfield, MA (US);

Jason Walther, Holliston, MA (US);

Jonathan Wang, Brighton, MA (US);

Kevin Victor Chen, Marlborough, MA (US);

Assignee:

Genzyme Corporation, Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
B01D 15/18 (2006.01); B01D 61/18 (2006.01); B01D 61/22 (2006.01); C12M 1/36 (2006.01); C12M 1/00 (2006.01); C12M 1/34 (2006.01);
U.S. Cl.
CPC ...
C12M 41/48 (2013.01); B01D 15/1807 (2013.01); B01D 61/18 (2013.01); B01D 61/22 (2013.01); C12M 29/04 (2013.01); C12M 29/10 (2013.01); C12M 41/40 (2013.01); B01D 2311/2626 (2013.01); B01D 2311/2688 (2013.01); B01D 2313/243 (2013.01); B01D 2315/10 (2013.01); B01D 2317/04 (2013.01); B01D 2317/06 (2013.01);
Abstract

The disclosure provides a filtration system for a cell culture apparatus and a method of cell culture. The filtration system comprises a bioreactor vessel and two or more alternating tangential flow (ATF) filters connected in parallel. A failure in either filter is detected by an in-line sensor, and an automated response system functions to sequester the malfunctioning filter by stopping the flow of liquid media through the filter. Media flow through the remaining operable filters can be increased so that the rate of perfusion through the bioreactor remains relatively unchanged. Such a system may prevent issues that arise from ATF filter failures in conventional perfusion bioreactors, thereby improving the long-term viability of cell cultures.


Find Patent Forward Citations

Loading…